Device Trial Radar · NCT01234480
Intended Use Study of the BD SurePath Plus™ Pap
Last checked: Nov 20, 2026Latest source record: May 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
5,859
Actual
Start
Sep 2010
Primary completion
Mar 2012
Study completion Aug 2012
Sponsor
- Lead sponsor
- Becton, Dickinson and CompanyPublic (BDX)
- Sponsor type
- Industry
- First posted
- Nov 4, 2010
Design
- Study type
- Interventional
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- Female only, from 18 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will provide data on the performance of the BD SurePath Plus™ Pap test for identifying high grade cervical disease. This study will be conducted with approximately 12,500 women undergoing routine cervical cancer screening, of whom women with abnormal cytology and/or positive HPV test will be selected to undergo colposcopy and biopsy/ECC. Subjects with abnormal cytology results with biopsy results of less than or equal to CIN1 or CIN2 untreated will be asked to return in 6-8 months for follow-up testing. Subjects may be asked to proceed to a longer-term follow-up study and undergo cytological evaluation annually for 3 years (separate study).
Conditions
- Uterine Cervical Neoplasms
- Uterine Cervical Cancer
- Neoplasms, Squamous Cell
- Neoplasms, Glandular and Epithelial
- Neoplasms by Histologic Type
- Neoplasms
- Papilloma
Interventions
BD SurePath Plus Pap testDevice
BD SurePath Plus Pap test
BD SurePath Pap testDevice
BD SurePath Plus Pap test
colposcopy with biopsy/ECCProcedure
Colposcopy with biopsy/ECC for subjects with 1)BD SurePath Pap NILM, but HPV positive, or 2) BD SurePath Plus Pap test result of ASC-US or higher 3)BD SurePath Pap ASC-US or higher
HPV DNA testDevice
digene HC2 HPV DNA test
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity, Specificity, PPV, and NPV of BD SurePath Plus Pap Test for the Determination of Cervical Disease as Defined by CIN2 or HigherTime frame: 10 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seattle Women's: Health, Research, Gynecology
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.